Exela Pharma Sciences LLC

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Pfizer is laying off employees across its manufacturing facilities in Ireland, including at Grange Castle, Ringaskiddy and Newbridge. The workforce cuts will start in the last quarter of this year and will continue into next year, the company confirmed to Endpoints News in an email. No further details were given. Baxter Pharmaceuticals has closed it North Cove facility in Marion, NC, due to Hurricane Helene causing “excessive” rain and flooding damage. The company is working to get the site back up and running, and its utilizing the rest of its manufacturing network to try and mitigate any potential supply issues. While the full impact of the site closure has yet to be seen, this will have a “negative” impact on the company’s annual revenue, Baxter said in a release on Sunday. Recipharm announced on Thursday it’s expanding its clinical and commercial pharmaceutical development and manufacturing offerings. The CDMO is expanding its small molecule site in Bengaluru, India, by adding a lab for developing sterile products. The company has also added a manufacturing line at its Wasserburg, Germany, site and has expanded its site in Kaysersberg, France. No financial details were disclosed. Recipharm also partnered with US-based CDMO Exela Pharma Sciences this week, to expand sterile manufacturing offerings in the US, the company said on Tuesday. The new partnership will give Recipharm access to Exela’s factory in Lenoir, NC, which houses abilities in manufacturing sterile injectables in vials and pre-filled syringes. India-based CDMO Piramal Pharma Solutions is investing $80 million to expand its sterile injectable facility in Lexington, KY, the company said on Monday. The expansion will add 24,000 square feet of capacity, including a new laboratory and manufacturing space. The expansion is anticipated to be finished in the first quarter of 2027. Bill and Melinda Gates Foundation-backed TerraPower Isotopes is now commercially producing the radioisotope Actinium-225 , the company announced on Tuesday. California-based SK pharmteco is injecting $260 million to build a new small molecule and peptide manufacturing facility in Sejong, South Korea, the company said on Sunday. The 135,800 square-foot facility will house R&D facilities as well as clinical and commercial manufacturing capabilities. Operations are anticipated to start in late 2026. Radioisotope producer Nusano has raised over $115 million in a Series C funding round, the company said on Tuesday. The raise will be used to help the company launch new products, including non-carrier-added lutetium-177 and actinium-225. BioCryst Pharmaceuticals has been awarded a $69 million contract from the US Department of Health and Human Services, according to a Monday announcement. Under the new contract, BioCryst will supply up to 95,625 doses of its flu vaccine, Rapivab, to the US government’s national stockpile over five years. Cell therapy CDMO Excellos has been chosen by Galapagos to make its CAR-T cell therapy asset, dubbed GLPG5101, for a Phase 1/2 clinical trial in patients with relapsed or refractory non-Hodgkin lymphoma. Excellos will make the candidate at its site in San Diego, CA, according to the Tuesday press release. Ferring Pharmaceuticals has opened a new 25,000 square-meter manufacturing site in Kuopio, Finland, which will make drug substances for its gene therapy Adstiladrin, a treatment for patients with non-muscle invasive bladder cancer, the company said on Thursday. Ginkgo Bioworks and Virica Biotech are partnering to reduce the cost of manufacturing gene therapies, the companies said on Thursday. Both companies are providing and integrating their gene therapy manufacturing platforms to offer a combined service to customers.

Across both recalls, Pfizer and Hospira said they hadn’t received any side effect or safety reports as of Dec. 21. After a year plagued by recalls, Pfizer’s sterile injectables unit Hospira seems no closer to righting the ship over its glass-contamination woes. What’s more, the company’s latest product pulls threaten to intensify the ongoing shortages of several critical hospital drugs. Shortly before the holiday, Pfizer’s Hospira announced two separate recalls over the potential presence of glass particulates in vials and syringes of certain meds. In the case of injectable cancer medication bleomycin—of which Hospira is recalling one lot—a confirmed customer report alerted the company to the presence of glass particulates within a single vial, the company said in a notice posted on the FDA’s website. The second recall, which covers three drugs—two strengths of injectable sodium bicarbonate, plus one lot of atropine sulfate injection—kicked off after the company flagged “the potential presence of glass particulate matter” during routine product inspection. In both cases, Pfizer and Hospira said they hadn’t received any side effect or safety reports as of Dec. 21. Particulate contamination can have serious safety implications, and for hospital drugs especially so. Hospira, for its part, warned of the potential for “serious adverse events” should patients receive medications tainted with glass. Potential complications could include vein inflammation and the formulation of granulomas, or tiny clusters of white blood cells and tissue that arise as a reaction to infections and inflammation, irritants or foreign objects. Injecting a drug that contains glass particulates can also block vessels and lead to life-threatening blood clotting events, Hospira warned. “The frequency and severity of these adverse events could vary depending upon a variety of factors including the size and number of particles in the drug product, patient comorbidities (such as age, compromised organ function), and presence or absence of vascular anomalies,” Hospira noted in its press release. Thankfully, there are safeguards in place to prevent administration of a contaminated drug. Hospira pointed out that the labels for each drug covered in the recall contain statements directing healthcare professionals to visually inspect the products for particulate matter and discoloration prior to administration. The single batch of injectable bleomycin is stored in ONCO-TAIN glass fliptop vials, Hospira explained. The drug is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin is often used in conjunction with other chemotherapies and can be used to treat malignancies like non-Hodgkin’s lymphoma, testicular cancer, ovarian cancer and cervical cancer. The single bleomycin batch comes one vial to a carton, with 112 vials stored in each case. The units were due to expire on June 30, 2024. Injectable sodium bicarbonate, meanwhile, is indicated to treat a range of conditions, from metabolic acidosis—a potential complication of severe kidney disease—to uncontrolled diabetes, cardiac arrest and circulatory insufficiency due to shock or severe dehydration. The medication can also be used to help reverse the effects of certain drugs like barbiturates or treat poisoning by salicylates or methyl alcohol, among other uses. The batches of sodium bicarbonate 4.2% and sodium bicarbonate 8.4% were expected to be good until Jan. 1, 2025, and Mar. 1, 2025, respectively. The final drug covered in the recall, atropine sulfate injection, is given parenterally for the temporary blockade of severe or life-threatening muscarinic effects—for example, as an antidote for organophosphorus or muscarinic mushroom poisoning. The medication can also help patients suffering from bradyasystolic cardiac arrest. The single atropine lot was set to expire on Feb. 1, 2025. Despite the frequency of Hospira recalls this past year—often over similar particulate concerns—Pfizer noted in the company’s press release that it places the “utmost importance on patient safety and product quality at every step in the manufacturing and supply chain process.” Still, this is hardly Hospira’s first recall rodeo. Late last December, Hospira recalled one lot of its antibiotic vancomycin hydrochloride at the 1.5-gram dose because of glass particles in vials. Glass concerns cropped up again in October, when Hospira yanked a single batch of 4.2% sodium bicarbonate injection with an August 2024 expiration date. The company also recalled a 1% lidocaine HCI injection lot with a June 2024 expiration date and a 2% lidocaine HCI injection lot with a July 2024 expiration date. Hospira, which Pfizer purchased for $17 billion in 2015, has a history of recall problems. Back in 2017 and 2018, the company issued several recalls of injectables due to problems with particulates, microbial growth and a human hair found in a syringe of one lot of 25% dextrose injection for infants. Hospira’s latest recalls come at an especially inopportune time. According to the FDA’s drug shortage database, myriad strengths of injectable sodium bicarbonate are in shortage right now. Hospira, for its part, credited the supply squeeze to shipping delays and increased demand. Other companies caught up in the sodium bicarbonate shortfall include Exela, Amphastar and Fresenius Kabi. Atropine sulfate injection is also in shortage from a range of drugmakers, according to the FDA.

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. This week, we look into Eli Lilly joining Redwire’s initiative to manufacture pharmaceuticals in space, as well as Exela Pharma’s recall of three injectables. Daiichi Sankyo is absorbing two of its wholly-owned manufacturing companies, Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma , effective April 2025. Announced on Tuesday, the move expands Daiichi’s capacity to supply and manufacture antibody-drug conjugates, as well as develop new modalities. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.